Mangalam Drugs and Organics Ltd

Mangalam Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Mangalam Drugs and Organics Ltd

₹ 66.4 -0.02%
30 Oct 4:01 p.m.
mangalamdrugs.com BSE: 532637 NSE: MANGALAM
About

Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates[1]

Key Points

Business Overview:[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations

Website BSE NSE
  • Market Cap ₹ 105 Cr.
  • Current Price ₹ 66.4
  • High / Low ₹ 130 / 62.8
  • Stock P/E
  • Book Value ₹ 93.9
  • Dividend Yield 0.00 %
  • ROCE 8.03 %
  • ROE 4.71 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 0.70 times its book value
  • Company's working capital requirements have reduced from 22.9 days to 13.4 days

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 2.42% over past five years.
  • Company has a low return on equity of -0.20% over last 3 years.
  • Contingent liabilities of Rs.34.6 Cr.
  • Promoters have pledged or encumbered 34.6% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
109 108 63 91 87 82 97 102 77 80 89 73 57
99 100 57 91 91 79 90 91 68 71 80 63 62
Operating Profit 10 8 6 0 -3 2 7 12 8 9 9 10 -5
OPM % 9% 8% 10% 0% -4% 3% 7% 11% 11% 11% 10% 14% -8%
0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 4 3 3 3 3 3 3 4 4 4 3 4 4
Depreciation 3 3 3 3 3 4 4 4 4 4 4 5 4
Profit before tax 4 3 1 -6 -10 -5 0 4 1 1 1 2 -13
Tax % 29% 29% 16% -22% -7% -25% -920% 10% -356% -125% 5% 91% 6%
3 2 0 -4 -10 -4 0 4 3 3 1 0 -14
EPS in Rs 1.90 1.41 0.27 -2.77 -6.03 -2.25 0.32 2.24 1.69 1.70 0.88 0.09 -8.67
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
123 221 295 299 269 228 282 380 451 372 369 318 299
113 200 257 252 222 218 259 327 402 347 351 282 276
Operating Profit 10 20 38 47 47 10 24 53 49 26 17 36 23
OPM % 8% 9% 13% 16% 17% 4% 8% 14% 11% 7% 5% 11% 8%
0 0 0 -0 1 0 1 5 0 0 0 0 0
Interest 10 10 9 10 12 9 10 9 11 13 14 15 15
Depreciation 4 4 4 5 7 7 8 9 10 11 15 16 17
Profit before tax -4 6 24 31 29 -6 6 40 28 2 -11 5 -9
Tax % -22% -2% 33% 29% 32% 40% -32% 29% 29% 43% -18% -39%
-3 6 16 22 20 -8 8 28 20 1 -9 7 -9
EPS in Rs -2.31 4.66 11.15 14.08 12.57 -5.07 5.21 17.67 12.42 0.80 -5.72 4.37 -6.00
Dividend Payout % 0% 0% 0% 0% 4% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 4%
5 Years: 2%
3 Years: -11%
TTM: -16%
Compounded Profit Growth
10 Years: 1%
5 Years: -4%
3 Years: -30%
TTM: -399%
Stock Price CAGR
10 Years: -8%
5 Years: -15%
3 Years: -22%
1 Year: -41%
Return on Equity
10 Years: 9%
5 Years: 7%
3 Years: 0%
Last Year: 5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 13 13 14 16 16 16 16 16 16 16 16 16
Reserves 10 16 47 70 88 80 88 115 135 136 127 133
77 78 60 66 69 65 52 70 88 89 107 96
25 63 38 38 54 50 75 64 90 117 108 114
Total Liabilities 125 170 160 190 227 211 231 264 328 358 357 359
53 53 54 93 102 103 101 118 135 142 147 156
CWIP 0 0 5 0 0 0 1 6 6 9 8 3
Investments 0 0 0 2 0 0 0 0 0 0 0 0
72 117 100 95 125 107 128 140 188 206 202 201
Total Assets 125 170 160 190 227 211 231 264 328 358 357 359

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
7 14 22 43 25 22 31 28 26 38 12 43
-2 -4 -11 -39 -16 -9 -7 -31 -27 -22 -18 -19
-5 -10 -11 -3 -9 -11 -23 3 3 -17 6 -22
Net Cash Flow 0 1 -0 0 -0 1 0 -1 1 -1 -0 2

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 88 73 37 45 61 28 52 52 38 46 28 45
Inventory Days 170 134 85 69 132 175 121 85 139 200 185 303
Days Payable 97 128 37 38 82 77 106 63 65 139 124 199
Cash Conversion Cycle 161 79 85 75 111 126 67 74 112 107 88 148
Working Capital Days 29 26 32 19 31 21 10 23 43 38 18 13
ROCE % 6% 16% 29% 31% 25% 2% 11% 27% 18% 6% 1% 8%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
50.31% 50.31% 50.31% 50.31% 50.31% 50.31% 50.31% 50.30% 50.30% 50.30% 50.30% 50.30%
0.10% 0.10% 0.10% 0.10% 0.10% 0.26% 0.21% 0.11% 0.11% 0.47% 0.53% 0.11%
49.58% 49.59% 49.58% 49.59% 49.59% 49.42% 49.47% 49.58% 49.58% 49.23% 49.16% 49.57%
No. of Shareholders 17,91117,94317,89017,97818,61019,17319,31219,50819,67919,69719,72819,881

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls

  • Aug 2016
    Transcript
    Notes
    PPT
  • May 2016
    Transcript
    Notes
    PPT
  • Feb 2016
    Transcript
    Notes
    PPT